Reasons for low uptake of a psychological intervention offered to cancer survivors with elevated depressive symptoms.


Journal

Psycho-oncology
ISSN: 1099-1611
Titre abrégé: Psychooncology
Pays: England
ID NLM: 9214524

Informations de publication

Date de publication:
04 2019
Historique:
received: 02 10 2018
revised: 08 02 2019
accepted: 08 02 2019
pubmed: 15 2 2019
medline: 25 2 2020
entrez: 15 2 2019
Statut: ppublish

Résumé

In line with screening guidelines, cancer survivors were consecutively screened on depressive symptoms (as part of standard care), with those reporting elevated levels of symptoms offered psychological care as part of a trial. Because of the low uptake, no conclusions could be drawn about the interventions' efficacy. Given the trial set-up (following screening guidelines and strict methodological quality criteria), we believe that this observational study reporting the flow of participation, reasons for and characteristics associated with nonparticipation, adds to the debate about the feasibility and efficiency of screening guidelines. Two thousand six hundred eight medium- to long-term cancer survivors were consecutively screened on depressive symptoms using the Patient Health Questionnaire-9 (PHQ-9). Those with moderate depressive symptoms (PHQ-9 ≥ 10) were contacted and informed about the trial. Patient flow and reasons for nonparticipation were carefully monitored. One thousand thirty seven survivors (74.3%) returned the questionnaire, with 147 (7.6%) reporting moderate depressive symptoms. Of this group, 49 survivors (33.3%) were ineligible, including 26 survivors (17.7%) already receiving treatment and another 44 survivors (30.0%) reporting no need for treatment. Only 25 survivors (1.0%) participated in the trial. Of the approached survivors for screening, only 1% was eligible and interested in receiving psychological care as part of our trial. Four reasons for nonparticipation were: nonresponse to screening, low levels of depressive symptoms, no need, or already receiving care. Our findings question whether to spend the limited resources in psycho-oncological care on following screening guidelines and the efficiency of using consecutive screening for trial recruitment in cancer survivors.

Identifiants

pubmed: 30762273
doi: 10.1002/pon.5029
pmc: PMC6593801
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

830-838

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2019 The Authors. Psycho-Oncology Published by John Wiley & Sons Ltd.

Références

Psychooncology. 2018 Aug;27(8):2056-2059
pubmed: 29808508
Lancet Oncol. 2013 Jul;14(8):721-32
pubmed: 23759376
J Clin Oncol. 2012 Apr 10;30(11):1187-96
pubmed: 22412144
Lancet Oncol. 2014 Sep;15(10):1168-76
pubmed: 25175097
Psychooncology. 2018 Mar;27(3):900-907
pubmed: 29239060
Gen Hosp Psychiatry. 2008 Mar-Apr;30(2):112-26
pubmed: 18291293
Psychooncology. 2019 Apr;28(4):830-838
pubmed: 30762273
Psychooncology. 2011 Jun;20(6):655-63
pubmed: 21381148
Ann Intern Med. 2001 Apr 17;134(8):663-94
pubmed: 11304107
Eur J Cancer. 2017 Feb;72:46-53
pubmed: 28024266
Cancer. 2017 Nov 1;123(21):4236-4243
pubmed: 28654189
Support Care Cancer. 2011 Jul;19(7):871-81
pubmed: 21369722
Diabet Med. 2013 Jan;30(1):88-94
pubmed: 22924587
Lancet. 2014 Sep 20;384(9948):1099-108
pubmed: 25175478
J Clin Oncol. 2008 Feb 10;26(5):768-77
pubmed: 18258985
Psychooncology. 2014 May;23(5):516-23
pubmed: 24829951
Psychooncology. 2016 Nov;25(11):1363-1370
pubmed: 26804486
J Clin Oncol. 2013 Feb 20;31(6):782-93
pubmed: 23319686
Emerg Med J. 2003 Mar;20(2):164-8
pubmed: 12642531
Psychol Med. 2014 Apr;44(5):897-907
pubmed: 23778105
Cochrane Database Syst Rev. 2012 Nov 14;11:CD007064
pubmed: 23152241
Cancer. 2008 Aug 15;113(4):870-8
pubmed: 18618581
J Natl Cancer Inst Monogr. 2004;(32):57-71
pubmed: 15263042
BMC Psychiatry. 2016 Feb 02;16:22
pubmed: 26831145
CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
pubmed: 24890451
Psychooncology. 2014 Feb;23(2):121-30
pubmed: 24105788
Lancet. 2008 Jul 5;372(9632):40-8
pubmed: 18603157
CA Cancer J Clin. 2008 Jul-Aug;58(4):214-30
pubmed: 18558664
Psychooncology. 2011 May;20(5):525-31
pubmed: 20878852
J Clin Oncol. 2012 Apr 10;30(11):1160-77
pubmed: 22412146
Br J Cancer. 2006 Feb 13;94(3):372-90
pubmed: 16465173
J Psychosom Res. 2008 Apr;64(4):383-91
pubmed: 18374737
Psychooncology. 2018 Sep;27(9):2063-2076
pubmed: 29885258
J Gen Intern Med. 2000 Aug;15(8):527-34
pubmed: 10940143
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
J Natl Cancer Inst Monogr. 2004;(32):9-16
pubmed: 15263035
PLoS One. 2011;6(11):e27181
pubmed: 22110613
Psychooncology. 2015 Jul;24(7):812-8
pubmed: 25504987
CMAJ. 2018 Jan 15;190(2):E44-E49
pubmed: 29335262

Auteurs

Loek J van der Donk (LJ)

Department of Health Psychology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

K Annika Tovote (KA)

Department of Health Psychology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Thera P Links (TP)

Department of Endocrinology and Metabolic Diseases University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Jan L N Roodenburg (JLN)

Department of Oral and Maxillofacial Surgery, Section of Oncology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Johanna C Kluin-Nelemans (JC)

Department of Haematology, University of Groningen, University Medical Center Groningen Groningen, Groningen, the Netherlands.

Henriette J G Arts (HJG)

Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Veronique E M Mul (VEM)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, the Netherlands.

Robert J van Ginkel (RJ)

Department of Surgery, Laboratory for Translational Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Peter C Baas (PC)

Department of Surgery, Martini Hospital, Groningen, the Netherlands.

Christiaan Hoff (C)

Department of Surgery, Medical Center Leeuwarden, Leeuwarden, the Netherlands.

Robbert Sanderman (R)

Department of Health Psychology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Department of Psychology, Health and Technology, University of Twente, Enschede, the Netherlands.

Joke Fleer (J)

Department of Health Psychology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Maya J Schroevers (MJ)

Department of Health Psychology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH